Similar to themice receiving ANXA2 shRNA, mice in the ANXA2 antibody groupdied due to tumor progression at the splenic bed, suggesting this anti-ANXA2antibody therapy does not inhibit the growth of primary PDAs. This evidence concerns the gene ANXA2 and neoplasm.